comparative effectiveness

Gary Lyman, MD, MPH, co-director of the Hutchinson Institute for Cancer Outcomes Research (HICOR) discusses the inspiration, key findings, and overall goals of HICOR’s first-of-its-kind community cancer care report, “Community Cancer Care in Washington State: Quality and Cost Report.”
The results from a randomized controlled trial were compared with a real-world cohort for the safety and efficacy of a biosimilar to treat chemotherapy-induced neutropenia in patients with breast cancer.
A new study examined post-treatment evaluation methods of head and neck squamous cell carcinoma in the context of advanced imaging and value-based care.
A comparative effectiveness study examined clinical outcomes and costs after treatment with a febrile neutropenia therapy vs a biosimilar for patients with non-myeloid cancer undergoing chemotherapy.
A new economic model may help clinicians and payers have a better understanding of the relative clinical benefits and costs of second-line treatment options for metastatic renal cell carcinoma.
A study presented at the European Lung Cancer Congress investigated the effects of multiple therapies on symptom management in ALK-positive non-small cell lung cancer.
A featured poster session at the SGO 2018 Annual Meeting on Women’s Cancer detailed the results of a study comparing the efficacy and tolerability of PARP inhibitors as maintenance treatment in BRCA-mutated platinum-sensitive relapsed ovarian cancer.
A recent study investigated whether risk-standardized mortality rate is an effective predictor of long-term survival in hospitalized patients with heart failure.
A recent study compared the effects of a collaborative care intervention vs usual care on health status of patients with chronic heart failure.
Commercial payers are spending almost twice as much on chemotherapy administered in hospital outpatient departments compared with therapy administered in physician offices.